{"relevance": {"rules": [{"rule_id": "relevance_rule_1", "rule_text": "All abstracts that coincide with disease area of interest (IgA Nephropathy)", "processing_type": "keyword_filtering", "include_logic": {"any_of": [{"categories": ["Disease", "Clinical Trial", "Company", "Treatment", "Treatment Class", "Endpoints", "Other"], "field": "keywords", "values": ["IgA Nephropathy", "PROTECT", "ALIGN", "ORIGIN 3", "RUBY-3", "NCT05799287", "VISONARY", "APPLAUSE", "Novartis", "Roche", "Travere Therapeutics", "Otsuka", "Vera Therapeutics", "Alpine Immune Sciences", "Vertex Pharmaceuticals", "Remegen", "Chinook Therapeutics", "Veloxis", "Asahi Kasei", "Proteinuria", "UPCR", "UACR", "eGFR", "KDIGO", "Remission", "Disease modification", "IgA-IgG immune complexes", "Subgroup", "immunosuppression", "non-immunosuppression", "pathogenic Mechanisms", "B cell depletion +/- B cell activation +/- B cell targeting", "MEST-C", "treatment options", "Clinical Trial Endpoints", "Biomarkers", "Complement proteins +/- C3 Complement +/- C4 Complement", "Standard of care", "targeted-release formulation budesonide", "Telitacicept", "Sparsentan", "Iptacopan", "Atrasentan", "Zigakibart", "Povetacicept", "Sibeprenlimab", "Atacicept", "Methylprednisone +/- methylprednisolone", "BAFF +/- APRIL; OR APRIL alone; OR BAFF/April; OR Blys/April; OR APRIL/BLyS", "AT1/EDNRA antagonist? +/- ERA +/- endothelian receptor antagonist", "Complement Factor B inhibitor +/- alternative pathway +/- complement inhibition +/- complement system inhibitors", "ENDR Antagonist", "Systemic steroid +/- Systemic glucocorticoid +/- Systemic corticosteroid", "SGLT2 +/- inhibition", "optimized supportive care +/- ACE/ARB +/- RASi +/- RAASi", "Gd-IgA OR IgA1 OR Gd-IgA1 OR Galactose deficient", "Immune Complex", "budesonide", "prednisone", "TRF budesonide", "Tarpeyo", "Kinpeygo"]}]}, "exclude_logic": ""}]}, "priorities": {"Very High": {"rules": [{"rule_id": "very_high_rule_1", "rule_text": "Abstracts assigned by the Calliditas team", "processing_type": "none", "include_logic": {"any_of": [{"categories": ["Assignment"], "field": "assigned_by_calliditas", "values": ["true"]}]}, "exclude_logic": ""}]}, "Internal": {"rules": [{"rule_id": "internal_rule_1", "rule_text": "Calliditas sponsored studies", "processing_type": "keyword_filtering", "include_logic": {"any_of": [{"categories": ["Sponsor"], "field": "keywords", "values": ["Calliditas"]}]}, "exclude_logic": ""}]}, "High": {"rules": [{"rule_id": "high_rule_1", "rule_text": "All relevant abstracts that include Phase 2/3 data (including meta-analyses), real-world data (including patient reported outcomes, retrospective analyses and registry data)", "processing_type": "context_filtering", "include_logic": {"any_of": [{"categories": ["Study Type", "Data Type"], "field": "keywords", "values": ["Phase 2", "Phase 3", "Phase 2/3", "meta-analyses", "real-world data", "patient reported outcomes", "retrospective analyses", "registry data"]}]}, "exclude_logic": ""}]}, "Medium": {"rules": [{"rule_id": "medium_rule_1", "rule_text": "All relevant abstracts that include Phase 1 data, general HEOR studies, prognostic studies, preclinical studies, or other general studies", "processing_type": "context_filtering", "include_logic": {"any_of": [{"categories": ["Study Type"], "field": "keywords", "values": ["Phase 1", "HEOR", "health economics and outcomes research", "prognostic studies", "preclinical studies", "general studies"]}]}, "exclude_logic": ""}]}, "Low": {"rules": [{"rule_id": "low_rule_1", "rule_text": "All relevant abstracts that only have mention of an indication of interest and does not include any other data", "processing_type": "context_filtering", "include_logic": {"any_of": [{"categories": ["Disease"], "field": "keywords", "values": ["IgA Nephropathy"]}]}, "exclude_logic": {"any_of": [{"categories": ["Study Type", "Data Type", "Treatment", "Treatment Class", "Endpoints", "Other"], "field": "keywords", "values": ["Phase 1", "Phase 2", "Phase 3", "Phase 2/3", "meta-analyses", "real-world data", "patient reported outcomes", "retrospective analyses", "registry data", "HEOR", "health economics and outcomes research", "prognostic studies", "preclinical studies", "general studies", "Telitacicept", "Sparsentan", "Iptacopan", "Atrasentan", "Zigakibart", "Povetacicept", "Sibeprenlimab", "Atacicept", "Methylprednisone +/- methylprednisolone", "BAFF +/- APRIL; OR APRIL alone; OR BAFF/April; OR Blys/April; OR APRIL/BLyS", "AT1/EDNRA antagonist? +/- ERA +/- endothelian receptor antagonist", "Complement Factor B inhibitor +/- alternative pathway +/- complement inhibition +/- complement system inhibitors", "ENDR Antagonist", "Systemic steroid +/- Systemic glucocorticoid +/- Systemic corticosteroid", "SGLT2 +/- inhibition", "optimized supportive care +/- ACE/ARB +/- RASi +/- RAASi", "Immune Complex", "budesonide", "prednisone", "TRF budesonide", "Tarpeyo", "Kinpeygo", "targeted-release formulation budesonide", "Proteinuria", "UPCR", "UACR", "eGFR", "KDIGO", "Remission", "Disease modification", "IgA-IgG immune complexes", "Subgroup", "immunosuppression", "non-immunosuppression", "pathogenic Mechanisms", "B cell depletion +/- B cell activation +/- B cell targeting", "MEST-C", "treatment options", "Clinical Trial Endpoints", "Biomarkers", "Complement proteins +/- C3 Complement +/- C4 Complement", "Standard of care", "Gd-IgA OR IgA1 OR Gd-IgA1 OR Galactose deficient"]}]}}]}}}